Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2016—Olympus announced that the American Urological Association, together with the Society of Urologic Oncology, included the Olympus Narrow Band Imaging (NBI) technology in its newly released guideline for the diagnosis and treatment of non-muscle invasive bladder cancer.
November 2016—Qiagen launched its Paxgene Blood ccfDNA Tube for venous whole blood collection and room temperature stabilization of in vivo circulating cell-free DNA profiles.
November 2016—Horizon Discovery has entered into a co-development and commercialization agreement with Ventana Medical Systems, a member of the Roche group. The agreement covers the development, manufacture, and commercialization of cell-line derivative materials for use as immunohistochemistry reference standards in cancer tissue diagnostics to support the development and validation of IHC assays.
November 2016—MilliporeSigma introduced its Certified Spiking Solution of intact, heavy labeled thyroglobulin in SigMatrix, a synthetic surrogate serum.
November 2016—Siemens Healthineers released a software upgrade for its RapidComm Data Management System version 6.0, an informatics solution to centrally manage in vitro diagnostics analyzers and operators at the point of care. In addition to the system’s enhanced productivity and performance features, RapidComm V6.0 now connects with POC cardiac devices.
November 2016—Aalto Bio Reagents, a developer and provider of raw materials to the in vitro diagnostics industry and to research laboratories worldwide, announced the availability of its Tri-Plex suite of proteins and antibodies, which include its Zika Virus primary Envelope and NS1 proteins plus Chikungunya E2 wild type, E1 mutant, and E1 wild type proteins, and a complete set of Dengue virus proteins for serotypes 1–4.
November 2016—nzo Life Sciences introduced its new line of in situ hybridization and immunohistochemistry reagents for use with Enzo’s Highdef chromogens in ISH and IHC applications.
November 2016—Mindray has received 510(k) clearance from the Food and Drug Administration to market and sell the Mindray BC-5390 Auto Hematology Analyzer. The Mindray BC-5390 analyzer is designed to meet the testing needs of mid-volume hematology laboratories while offering features commonly found on large-volume analyzers.
November 2016—Sarstedt offers low protein binding micro tubes in 0.5 mL, 1.5 mL, and 2.0 mL volumes. These tubes are designed to meet the requirements of protein analytics while maximizing protein recovery rates. The micro tubes are manufactured from a proprietary polypropylene with low protein binding properties and do not feature any potentially contaminating surface coating like silicone.
November 2016—Meridian Life Science released a new catalog that provides a detailed overview of the company’s cardiac and metabolic markers for assay development. Meridian’s top-performing cardiac and metabolic markers include Lp-PLA2, CRP, D-dimer, troponin, NT-proBNP, myoglobin, procalcitonin, FABP, PAPP-A, fibrinogen, sCD40L, MPO, NSE, and galectin-3.
